Relmada Therapeutics (RLMD) Stock Highlights

0.63 | -77.26%

2024-12-05 06:08:55

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Statistics

Range Today

0.62 0.73

Volume Today 17.73M

Range 1 Year

1.88 7.22

Volume 1 Year 48.19M

Range 3 Year

1.81 38.68

Volume 3 Year 240.86M

Range 10 Year

1.81 79.6

Volume 10 Year 321.33M

Highlights

Market Capitalization 98.97M (small)

Floating Shares 27.54M

Current Price 0.63

Price To Earnings -1.13

Price To Book 1.16

Earnings Per Share -2.87

Payout Ratio 0%

Performance

Latest -77.26%

1 Month -82%

3 Months -76.84%

6 Months -80.13%

1 Year -75%

3 Years -96.32%

5 Years -98.35%

10 Years -98.91%

Benchmarks

Market Capitalization

35 / 54

Gross Profits

0 / 39

Total Revenue

0 / 50

Total Rank

52 / 54

Free Cashflow

46 / 54

Performance 5 years

46 / 54

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.